NEW YORK—Covington advised Lantheus Holdings, Inc. in its definitive agreement to acquire Life Molecular Imaging Limited, a subsidiary of Life Healthcare Group Holdings Limited.
Under the terms of the agreement between Lantheus Medical Imaging, Inc., Lantheus Radiopharmaceuticals UK Limited, Life Medical Group Limited, and Life Healthcare Group Holdings Limited, Lantheus UK will pay an upfront amount of $350 million, payable in cash at closing, and potential additional net sales earnout and milestone payments in an aggregate additional cash amount of up to $400 million. In addition, Lantheus UK may pay up to $30 million towards Life Medical Group’s retained future contingent liabilities under certain contractual arrangements.
Lantheus is a radiopharmaceutical-focused company delivering life-changing science to enable clinicians to Find, Fight, and Follow disease to deliver better patient outcomes.
Life Molecular Imaging is a global radiopharmaceutical company dedicated to developing and offering novel cutting-edge radiopharmaceuticals that improve early detection and characterization of chronic and life-threatening diseases.
Life Healthcare is a diversified healthcare organization that has over 40 years’ experience in the South African private healthcare sector.
The Covington team included: Jack Bodner, Gregor Frizzel, Ross Finnie, Olivia Scalise Gaspar, and Matthew Young (M&A); Winsome Cheung, Erica Wu, Katrina Alfano, Oliver Hodgkiss, Susan Hwang, and Robert Kim (life sciences transactions); Guy Dingley (tax); Sinan Utku, Priscilla Dodson, and Moritz Husch (IP); Robin Blaney, Michael Stern, and Natalie Maas (regulatory); Antonio Michaelides, Jenna Wallace, Brady McDaniel, and Richard Rowlands (employment and executive compensation); Megan Gates and Keunjung Cho (U.S. securities); Josh Gray (privacy and IT); Henning Bloss, Jan Friedeborn, and Maximilian Aretz (German law); and Deon Govender (South African law).
Back
